Intech Investment Management LLC Reduces Stock Holdings in DexCom, Inc. $DXCM

Key Points

• Intech Investment Management LLC reduced its stake in DexCom, Inc. by 9.9%, now holding approximately 0.14% of the company after selling 61,705 shares.
• DexCom reported quarterly earnings of $0.48 per share, exceeding analyst estimates, with a year-over-year revenue increase of 15.2% to $1.16 billion.
• Several hedge funds increased their holdings in DexCom, with Brighton Jones LLC boosting their stake by 257.7% during the last quarter.

Intech Investment Management LLC lowered its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 9.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 561,083 shares of the medical device company's stock after selling 61,705 shares during the quarter. Intech Investment Management LLC owned about 0.14% of DexCom worth $38,316,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of DexCom by 2.0% in the first quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company's stock worth $3,240,763,000 after buying an additional 925,882 shares during the period. Jennison Associates LLC raised its stake in shares of DexCom by 37.7% in the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after buying an additional 2,879,489 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company's stock worth $691,336,000 after buying an additional 1,868,241 shares during the period. Nuveen LLC bought a new position in shares of DexCom in the first quarter worth about $554,893,000. Finally, Raymond James Financial Inc. raised its stake in shares of DexCom by 21.8% in the first quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company's stock worth $229,117,000 after buying an additional 601,088 shares during the period. Institutional investors own 97.75% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on DXCM. UBS Group raised their price objective on DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Argus began coverage on DexCom in a research note on Thursday, August 21st. They set a "buy" rating and a $100.00 target price on the stock. Oppenheimer downgraded DexCom from an "outperform" rating to a "market perform" rating in a research note on Monday. Raymond James Financial lifted their target price on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. Finally, The Goldman Sachs Group began coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $99.89.

DexCom Price Performance

NASDAQ DXCM traded up $0.22 during trading on Friday, hitting $76.22. 3,054,556 shares of the stock traded hands, compared to its average volume of 3,987,928. The company has a market capitalization of $29.89 billion, a P/E ratio of 52.93, a price-to-earnings-growth ratio of 1.59 and a beta of 1.48. The firm has a 50-day simple moving average of $80.88 and a 200-day simple moving average of $78.72. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm's revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares in the company, valued at $1,832,853.62. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $88.99, for a total value of $130,459.34. Following the transaction, the executive vice president owned 106,689 shares of the company's stock, valued at $9,494,254.11. This represents a 1.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,237 shares of company stock worth $1,263,480 over the last three months. 0.32% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.